

L22 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:491052 CAPLUS

DN 139:57948

TI Liquid bisphosphonate formulations for bone disorders

IN Daifotis, Anastasia G.; Leung, Albert T.; Bergquist, Paul A.; Denker, Andrew

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003051373	A1	20030626	WO 2002-US38200	20021126
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
	US 2003139378	A1	20030724	US 2002-305868	20021126
	EP 1458400	A1	20040922	EP 2002-784653	20021126
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK	

PRAI US 2001-340965P P 20011213

WO 2002-US38200 W 20021126

AB The present invention relates to high dose oral liquid formulations of bisphosphonate and their methods of use to treat/prevent diseases to bone remodeling or bone disorders, such as for example, Paget's disease, osteoporosis, metastatic bone disease, hypercalcemia of malignancy, periprosthetic osteolysis, periodontal disease, arthritic conditions, and the like, while minimizing the potential for esophageal irritation and other adverse gastrointestinal effects. These methods comprise orally administering to a mammal the liquid pharmaceutical composition of at least 1 bisphosphonate, or a salt, as a unit dosage according to a continuous schedule having a once-weekly, twice-weekly, biweekly, twice-monthly, or monthly dosing interval. Thus, a formulation contained **alendronate monosodium trihydrate** 2.454, and sodium citrate **dihydrate** 21.18 mg/mL, NaOH and HCl qs to pH 6.8, and water qs to 1.00 mL.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:161293 CAPLUS

DN 132:199040

TI Sodium **alendronate** hydrates, processes for their manufacture, and pharmaceutical compositions containing them

IN Finkelstein, Nina; Lidor-Hadas, Ramy; Aronhime, Judith

PA Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.

SO PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000012517	A1	20000309	WO 1999-US19838	19990827
	W:			AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,	

MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2341459	AA	20000309	CA 1999-2341459	19990827
AU 9956988	A1	20000321	AU 1999-56988	19990827
EP 1107974	A1	20010620	EP 1999-944004	19990827

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

US 6281381	B1	20010828	US 1999-384145	19990827
SI 20581	C	20011231	SI 1999-20070	19990827
BR 9913472	A	20020305	BR 1999-13472	19990827
EE 200100126	A	20020617	EE 2001-126	19990827
JP 2002523514	T2	20020730	JP 2000-567539	19990827
NZ 510682	A	20030926	NZ 1999-510682	19990827
ZA 2001001451	A	20020221	ZA 2001-1451	20010221
NO 2001000957	A	20010426	NO 2001-957	20010226
BG 105292	A	20011231	BG 2001-105292	20010226
LT 4888	B	20020225	LT 2001-16	20010226
LV 12720	B	20020220	LV 2001-26	20010405
US 2003065214	A1	20030403	US 2001-898756	20010703
US 6696601	B2	20040224		
US 2004158098	A1	20040812	US 2003-751237	20031231
PRAI US 1998-98313P	P	19980827		
US 1999-129743P	P	19990416		
US 1999-144461P	P	19990719		
US 1999-384145	A1	19990827		
WO 1999-US19838	W	19990827		
US 2001-898756	A1	20010703		

AB New **hydrate** forms of **alendronate** sodium, having water content of approx. 1-12%, and processes for their manufacture, are disclosed. New crystalline forms of **alendronate** sodium B, D, E, F, G and H, and processes for manufacturing them, are also disclosed. These new forms of **alendronate** sodium are suitable for incorporation into pharmaceutical compns. for combating bone resorption in bone diseases.

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

(FILE 'HOME' ENTERED AT 13:44:13 ON 03 APR 2005)

FILE 'REGISTRY' ENTERED AT 13:44:29 ON 03 APR 2005

L1 0 S SODIUM ALENDRONATE DIHYDRATE/CN
L2 1 S 260055-09-2/RN
L3 0 S ABSOLUTE ETHANOL/CN
L4 1 S ETHANOL/CN

FILE 'CAPLUS, CAOLD' ENTERED AT 13:52:21 ON 03 APR 2005

L5 0 S L2 AND ABSOLUTE ETHANOL
L6 99 S ABSOLUTE ETHANOL
L7 0 S L6 AND ALENDRON?
L8 0 S L6 AND ?HYDRATE
L9 0 S L6 AND MOLECULAR SIEVES
L10 0 S L6 AND MOLECULAR SIEVE
L11 1 S L6 AND MOLECULAR
L12 5 S L6 AND DRYING
L13 1 S L12 AND REFLUX?
L14 2 S ?HYDROXYLBUTYLIDENE?
L15 0 S L14 AND L6
L16 1170 S ALENDRON?
L17 75 S L16 AND ?HYDRATE
L18 0 S L17 AND MOLECULAR SIEVE
L19 0 S L17 AND L6
L20 226476 S ETHANOL
L21 2 S L17 AND L4
L22 2 DUP REM L21 (0 DUPLICATES REMOVED)

(FILE 'HOME' ENTERED AT 13:44:13 ON 03 APR 2005)

FILE 'REGISTRY' ENTERED AT 13:44:29 ON 03 APR 2005

L1 0 S SODIUM ALENDRONATE DIHYDRATE/CN
L2 1 S 260055-09-2/RN
L3 0 S ABSOLUTE ETHANOL/CN
L4 1 S ETHANOL/CN

FILE 'CAPLUS, CAOLD' ENTERED AT 13:52:21 ON 03 APR 2005

L5 0 S L2 AND ABSOLUTE ETHANOL
L6 99 S ABSOLUTE ETHANOL
L7 0 S L6 AND ALENDRON?
L8 0 S L6 AND ?HYDRATE
L9 0 S L6 AND MOLECULAR SIEVES
L10 0 S L6 AND MOLECULAR SIEVE
L11 1 S L6 AND MOLECULAR
L12 5 S L6 AND DRYING
L13 1 S L12 AND REFLUX?
L14 2 S ?HYDROXYLBUTYLIDENE?
L15 0 S L14 AND L6
L16 1170 S ALENDRON?
L17 75 S L16 AND ?HYDRATE
L18 0 S L17 AND MOLECULAR SIEVE
L19 0 S L17 AND L6
L20 226476 S ETHANOL
L21 2 S L17 AND L4
L22 2 DUP REM L21 (0 DUPLICATES REMOVED)
L23 8 S L6 AND REFLUX?
L24 8 DUP REM L23 (0 DUPLICATES REMOVED)
L25 8 S L24 NOT L22
L26 8 S L24 NOT L14
L27 0 S L6 AND PHOSPHONIC
L28 1 S L6 AND PHOSPHON?
L29 54998 F HIS